Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
HYDROMOX (quinethazone) is an oral thiazide-type diuretic approved in 1963 for hypertension and edema management. As a small-molecule diuretic, it works by inhibiting sodium and chloride reabsorption in the distal convoluted tubule, reducing fluid volume and blood pressure. This legacy product represents a foundational class in cardiovascular therapeutics.
As an aging branded product approaching loss of exclusivity with moderate competitive pressure (30), expect limited team expansion and focus on profitability optimization rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on HYDROMOX represents a defensive career move focused on mature product management and managed care negotiations rather than growth or innovation. This role suits professionals seeking stability in a legacy brand or looking to develop cost-containment and payer management expertise in a high-pressure, low-growth environment.
Worked on HYDROMOX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.